Forskning ved Københavns Universitet - Københavns Universitet

Forside

AHRR (cg05575921) methylation extent of leukocyte DNA and lung cancer survival

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

AHRR (cg05575921) methylation extent of leukocyte DNA and lung cancer survival. / Kemp Jacobsen, Katja; Johansen, Jakob Sidenius; Mellemgaard, Anders; Bojesen, Stig Egil.

I: PLoS ONE, Bind 14, Nr. 2, e0211745, 2019.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Kemp Jacobsen, K, Johansen, JS, Mellemgaard, A & Bojesen, SE 2019, 'AHRR (cg05575921) methylation extent of leukocyte DNA and lung cancer survival', PLoS ONE, bind 14, nr. 2, e0211745. https://doi.org/10.1371/journal.pone.0211745

APA

Kemp Jacobsen, K., Johansen, J. S., Mellemgaard, A., & Bojesen, S. E. (2019). AHRR (cg05575921) methylation extent of leukocyte DNA and lung cancer survival. PLoS ONE, 14(2), [e0211745]. https://doi.org/10.1371/journal.pone.0211745

Vancouver

Kemp Jacobsen K, Johansen JS, Mellemgaard A, Bojesen SE. AHRR (cg05575921) methylation extent of leukocyte DNA and lung cancer survival. PLoS ONE. 2019;14(2). e0211745. https://doi.org/10.1371/journal.pone.0211745

Author

Kemp Jacobsen, Katja ; Johansen, Jakob Sidenius ; Mellemgaard, Anders ; Bojesen, Stig Egil. / AHRR (cg05575921) methylation extent of leukocyte DNA and lung cancer survival. I: PLoS ONE. 2019 ; Bind 14, Nr. 2.

Bibtex

@article{4ff077015a2c4ec0a0cc31baa04cbb2e,
title = "AHRR (cg05575921) methylation extent of leukocyte DNA and lung cancer survival",
abstract = "BACKGROUND: Prior studies have shown that AHRR (cg05575921) hypomethylation may be a marker of smoking, lung cancer risk and potentially lung cancer survival (in some lung cancer subtypes). It is unknown if AHRR (cg05575921) hypomethylation is associated with reduced survival among lung cancer patients.METHODS: In bisulfite treated leukocyte DNA from 465 lung cancer patients from the Copenhagen prospective lung cancer study, we measured AHRR (cg05575921) methylation. 380 died during max follow-up of 4.4 years. Cox proportional hazard models were used to analyze survival as a function of AHRR (cg05575921) methylation.RESULTS: We observed the expected inverse correlation between cumulative smoking and AHRR methylation, as methylation ({\%}) decreased (Coefficient -0.03; 95{\%} confidence interval, -0.04- -0.02, p = 8.6x10-15) for every pack-year. Cumulative smoking > 60 pack-years was associated with reduced survival (hazard ratio and 95{\%} confidence interval 1.48; 1.05-2.09), however, AHRR (cg05575921) methylation was not associated with survival when adjusted for sex, body mass index, smoking status, ethnicity, performance status, TNM Classification, and histology type of lung cancer.CONCLUSION: AHRR (cg05575921) methylation is linked to smoking but does not provide independent prognostic information in lung cancer patients.",
author = "{Kemp Jacobsen}, Katja and Johansen, {Jakob Sidenius} and Anders Mellemgaard and Bojesen, {Stig Egil}",
year = "2019",
doi = "10.1371/journal.pone.0211745",
language = "English",
volume = "14",
journal = "P L o S One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "2",

}

RIS

TY - JOUR

T1 - AHRR (cg05575921) methylation extent of leukocyte DNA and lung cancer survival

AU - Kemp Jacobsen, Katja

AU - Johansen, Jakob Sidenius

AU - Mellemgaard, Anders

AU - Bojesen, Stig Egil

PY - 2019

Y1 - 2019

N2 - BACKGROUND: Prior studies have shown that AHRR (cg05575921) hypomethylation may be a marker of smoking, lung cancer risk and potentially lung cancer survival (in some lung cancer subtypes). It is unknown if AHRR (cg05575921) hypomethylation is associated with reduced survival among lung cancer patients.METHODS: In bisulfite treated leukocyte DNA from 465 lung cancer patients from the Copenhagen prospective lung cancer study, we measured AHRR (cg05575921) methylation. 380 died during max follow-up of 4.4 years. Cox proportional hazard models were used to analyze survival as a function of AHRR (cg05575921) methylation.RESULTS: We observed the expected inverse correlation between cumulative smoking and AHRR methylation, as methylation (%) decreased (Coefficient -0.03; 95% confidence interval, -0.04- -0.02, p = 8.6x10-15) for every pack-year. Cumulative smoking > 60 pack-years was associated with reduced survival (hazard ratio and 95% confidence interval 1.48; 1.05-2.09), however, AHRR (cg05575921) methylation was not associated with survival when adjusted for sex, body mass index, smoking status, ethnicity, performance status, TNM Classification, and histology type of lung cancer.CONCLUSION: AHRR (cg05575921) methylation is linked to smoking but does not provide independent prognostic information in lung cancer patients.

AB - BACKGROUND: Prior studies have shown that AHRR (cg05575921) hypomethylation may be a marker of smoking, lung cancer risk and potentially lung cancer survival (in some lung cancer subtypes). It is unknown if AHRR (cg05575921) hypomethylation is associated with reduced survival among lung cancer patients.METHODS: In bisulfite treated leukocyte DNA from 465 lung cancer patients from the Copenhagen prospective lung cancer study, we measured AHRR (cg05575921) methylation. 380 died during max follow-up of 4.4 years. Cox proportional hazard models were used to analyze survival as a function of AHRR (cg05575921) methylation.RESULTS: We observed the expected inverse correlation between cumulative smoking and AHRR methylation, as methylation (%) decreased (Coefficient -0.03; 95% confidence interval, -0.04- -0.02, p = 8.6x10-15) for every pack-year. Cumulative smoking > 60 pack-years was associated with reduced survival (hazard ratio and 95% confidence interval 1.48; 1.05-2.09), however, AHRR (cg05575921) methylation was not associated with survival when adjusted for sex, body mass index, smoking status, ethnicity, performance status, TNM Classification, and histology type of lung cancer.CONCLUSION: AHRR (cg05575921) methylation is linked to smoking but does not provide independent prognostic information in lung cancer patients.

U2 - 10.1371/journal.pone.0211745

DO - 10.1371/journal.pone.0211745

M3 - Journal article

C2 - 30730943

VL - 14

JO - P L o S One

JF - P L o S One

SN - 1932-6203

IS - 2

M1 - e0211745

ER -

ID: 224599223